|
Arthur D. Levinson, Ph.D.
Chairman and Chief Executive Officer
Dr. Levinson became president and chief executive officer of Genentech
and joined the board of directors in 1995. He was named chairman
of the board of directors in 1999. Levinson joined the company in
1980 as a senior scientist and was named head of Research and Development
in 1993. He has been a member of Genentech's executive management
team since 1990. Prior to Levinson's employment with Genentech,
he was a postdoctoral fellow in the department of microbiology at
the University of California, San Francisco.
Susan D. Desmond-Hellmann, M.D., M.P.H.
President, Product Development
Dr. Hellmann joined Genentech in 1995 as a clinical scientist.
Following several promotions, Hellmann was named executive vice
president, Development and Product Operations, in 1999. In 2004,
she became president of Product Development. Prior to joining Genentech,
Hellmann was associate director of clinical cancer research at the
Bristol-Myers Squibb Pharmaceutical Research Institute. Trained
as an oncologist, Hellmann spent several years treating patients
in the clinical setting.
David A. Ebersman
Senior Vice President, Finance
Mr. Ebersman joined Genentech in 1994 as a business development
analyst. During the next several years, he was promoted to positions
of increasing responsibility in both Business Development and Product
Development. In 1999, Ebersman was named vice president, Product
Development, and in 2001, he was promoted to senior vice president,
Product Operations. In early 2004, Ebersman became a member of the
executive committee. Prior to joining Genentech, Ebersman was a
research analyst covering biotechnology investments for Oppenheimer
& Co., Inc., an investment banking firm. Mr. Ebersman will assume
the chief financial officer position in March 2005 upon Mr. Lavigne's
retirement.
|
|
Stephen G. Juelsgaard, D.V.M., J.D.
Executive Vice President, General Counsel and Secretary
Mr. Juelsgaard joined Genentech in 1985 as corporate counsel. In
1994, he was named vice president and general counsel. He was named
secretary in 1997 and executive vice president in 2002. Prior to
his employment with Genentech, Juelsgaard was an associate with
the law firm of Wilson Sonsini Goodrich & Rosati.
Louis J. Lavigne, Jr.
Executive Vice President and Chief Financial Officer
Mr. Lavigne joined Genentech in 1982 and, after several promotions,
assumed the chief financial officer position in September 1988.
He was named executive vice president in 1997. Prior to joining
Genentech, Lavigne held various financial management positions with
Pennwalt Corporation, a chemical and pharmaceutical company. Mr.
Lavigne will retire from Genentech in March 2005.
Myrtle S. Potter
President, Commercial Operations
Ms. Potter joined Genentech in 2000 as executive vice president,
Commercial Operations, and chief operating officer. She was promoted
to the role of president, Commercial Operations, in 2004. Before
joining Genentech, Potter was president of Bristol-Myers Squibb's
U.S. Cardiovascular/ Metabolics business. Prior to joining Bristol-Myers,
Potter spent 14 years at Merck & Co., Inc. in a variety of sales,
marketing and business planning roles.
Richard H. Scheller, Ph.D.
Executive Vice President, Research
Dr. Scheller joined Genentech in 2001 as senior vice president,
Research. He was named executive vice president of Research in 2003.
Prior to joining Genentech, Scheller served as professor of Molecular
and Cellular Physiology and of Biological Sciences at Stanford University
Medical Center for 19 years. In 1994, he became an investigator
at the Howard Hughes Medical Institute. Scheller has published more
than 200 papers in peer-reviewed scientific journals.
|
